TABLE 2.
Lack of effect of MR-1 treatment on sepsis in BALB/cByJ mice following i.v. inoculation of BG9163 pneumococci
| Treatmenta | Challenge dose (log10 CFU) | Mean log10 CFU/ml of blood ± SE on:
|
Days to death
|
No. alive: no. dead | |||
|---|---|---|---|---|---|---|---|
| Day 1 | Day 2 | Day 4 | Mean | Median | |||
| MR-1 | 4.48 | 4.5 ± 0.9 | 3.4 ± 0.5 | 3.1 ± 0.5 | 16.7 ± 2.8 | >21 | 4:2 |
| Hamster IgG | 4.48 | 4.2 ± 0.7 | 2.7 ± 0.6 | 3.6 ± 0.7 | 19.0 ± 2.0 | >21 | 5:1 |
| Ringer's | 4.48 | 5.2 ± 0.7 | 3.2 ± 0.8 | 3.5 ± 0.9 | 14.0 ± 4.1 | 2:2 | |
| MR-1 | 6.78 | 4.9 ± 0.3 | 6.6 ± 0.4 | 7.1 ± 0.5 | 3.3 ± 0.8 | 3 | 0:6 |
| Hamster IgG | 6.78 | 5.2 ± 0.3 | 7.2 ± 0.2 | 7.5 ± 0.1 | 2.5 ± 0.3 | 2 | 0:6 |
| Ringer's | 6.78 | 5.5 ± 0.3 | 7.0 ± 0.5 | 7.5 ± 0.3 | 2.5 ± 0.5 | 2 | 0:4 |
a
MR-1 protocol: 250 μg of MR-1 on day −1, day +1, and day 2. No MR-1 values differed from hamster IgG, or Ringer's at P < 0.05 for any of the comparisons.